Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.

byBenzinga Newsdesk

February 16, 2023

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.

Analyst Ratings

Analyst Ratings for Shopify

By Benzinga Insights

November 15, 12:27 PM

Shopify (NYSE:SHOP) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

SHOP

»TE Connectivity Q1 EPS $1.53 Beats $1.51 Estimate, Sales $3.84B Beat $3.76B Estimate

By Bill Haddad

January 25, 7:03 AM

TE Connectivity (NYSE:TEL) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.51 by 1.32 percent. This is a 13.07 percent decrease over earnings of $1.76 per share from the

TEL

Visa, Mastercard Halt Crypto Initiatives Pending Industry And Regulatory Recovery

By Anusuya Lahiri

March 1, 9:28 AM

After the industry meltdown, U.S. payment giants Visa Inc (NYSE: V) and Mastercard Inc (NYSE: MA) paused plans to forge new partnerships with crypto firms.

AXP

Protara Therapeutics Announces Presentation Of Additional Encouraging Data From Phase 1a ADVANCED-1 Trial Of TARA-002 In NMIBC At The 24th Annual Meeting Of The Society Of Urologic Oncology

By Benzinga Newsdesk

November 30, 9:37 AM

New results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBC As previously reported,

TARA

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target

Related Posts

Analyst Ratings for Shopify

»TE Connectivity Q1 EPS $1.53 Beats $1.51 Estimate, Sales $3.84B Beat $3.76B Estimate

Visa, Mastercard Halt Crypto Initiatives Pending Industry And Regulatory Recovery

Protara Therapeutics Announces Presentation Of Additional Encouraging Data From Phase 1a ADVANCED-1 Trial Of TARA-002 In NMIBC At The 24th Annual Meeting Of The Society Of Urologic Oncology